# Dexlansoprazole

## Dexilant delay-release 60mg

| TAH Drug Code      | [ODEXI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODEXI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of erosive esophagitis (EE) in patients aged 12 and above for up to 8 weeks. Maintenance of healed erosive esophagitis in patients aged 12 and above who have already healed from EE; in adults for up to 6 months， and in patients aged 12-17 for up to 16 weeks. Symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD) in patients aged 12 and above for a duration of 4 weeks.                                                                                                                                                                                                                                                                                                                           |
| Dosing             | Erosive esophagitis， Healing of all grades Age > 12 years-old， 60 mg orally once daily for up to 8 weeks. Erosive esophagitis， Maintenance of healing - Heartburn 30 mg orally once daily for up to 6 months. Gastroesophageal reflux disease， nonerosive 30 mg orally once daily for 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Known hypersensitivity (eg， anaphylaxis， anaphylactic shock， angioedema， bronchospasm， acute tubulointerstitial nephritis， urticaria) to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Abdominal pain (3.5-5%)， Diarrhea (4.7-5.1%)， Flatulence (1.4-2.6%)， Nausea (2.8-3.3%)， Vomiting (1.4-2.2%)， Nasopharyngitis (Pediatric， 5% or greater)， Pain， Oropharyngeal (Pediatric， 5% or greater)， Upper respiratory infection (1.7-2.9%). Serious: Cutaneous lupus erythematosus， Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Cobalamin deficiency (Rare)， Hypomagnesemia， Clostridium difficile diarrhea， Fundic gland polyposis of stomach， Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms， Hypersensitivity reaction (<2%)， Systemic lupus erythematosus， Fracture of bone (<2%)， Tubulointerstitial nephritis， acute. |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/dexlansoprazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

